Back to results
US 2022/0362297 A1Published application
Intracellular genomic transplant and methods of therapy
AssigneesRegents of the University of Minnesota, Intima Bioscience, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsBranden MORIARITY, Beau WEBBER, Modasir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
Life of this patent
Estimating the term…
Abstract
Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
Claims18
-150. (canceled)
A pharmaceutical composition comprising:
- (a) population of genetically modified immune cells comprising:
- (i) a genomic disruption in a cytokine inducible SH2-containing protein (CISH) gene target sequence;
- and
- (ii) an exogenous chimeric antigen receptor (CAR) or an exogenous T-cell receptor (TCR), wherein the exogenous CAR or the exogenous TCR target a tumor cell antigen, wherein the tumor cell antigen is a MUC-1 antigen or a CD70 antigen,
- wherein the population of genetically modified immune cells comprise a population of T cells, a population of NK cells, or a combination thereof, and
- (b) a pharmaceutically acceptable carrier or excipient.
3 more elements
A pharmaceutical compositions comprising:
- (a) population of genetically modified natural killer (NK) cells comprising:
- a genomic disruption in a cytokine inducible SH2-containing protein (CISH) gene target sequence and at least one additional genomic disruption in a transforming growth factor beta receptor II (TGFBRII) gene target sequence;
- and
- (b) a pharmaceutically acceptable carrier or excipient.
1 more element
Dependencies are inferred from the claim text.